

Peng MIN Shanghai Office



Language: Chinese, English

Expertise: Capital Markets Corporate Health & Life Sciences

Tel: +86 21 5068 0028

Email: minpeng@hylandslaw.com

基本信息

Education Background

2009-2012 | Shanghai University of International Business and Economics | International Law | Master

Working Experience

2012-2025 | Shanghai Dongfang Huayin Law Firm | Partner, Lawyer

2025-Present | Hylands Law Firm (Shanghai) | Partner

Professional Background

Min Peng focuses on domestic A-share capital markets legal practice. As the signing lawyer, he has successfully handled IPO, M&A reorganization, and refinancing projects for numerous companies. With a solid legal foundation and extensive practical experience, he employs a rigorous professional attitude and meticulous logical thinking to efficiently resolve various legal challenges in corporate capital operations, assisting companies in navigating key stages such as listing, financing, and resource integration to achieve value leap. In particular, through long-term dedication and in-depth research in the pharmaceutical industry, Min Peng has a profound understanding of the business models, technical barriers, and regulatory systems in subsectors such as chemical drugs, biologics, traditional Chinese medicine, CXO, and medical devices. He can accurately identify legal risk points throughout the entire chain of pharmaceutical enterprises, from R&D and production to registration and commercialization. He has been deeply involved in the commercial transactions and daily operations of multiple pharmaceutical companies, providing integrated legal support covering capital operations, drug R&D project initiation, registration and application, compliant production, and commercial operation.

Honors and Awards

Representative Cases

Capital Markets

Acted as the lead lawyer for the IPO of Huiyu Pharmaceutical (688553), assisting in its successful listing on the STAR Market of the Shanghai Stock Exchange.

Acted as the lead lawyer for the IPO of Roman (605289), assisting in its successful listing on the Main Board of the Shanghai Stock Exchange.

Acted as the lead lawyer for the IPO of Xinong (002942), assisting in its successful listing on the SME Board of the Shenzhen Stock Exchange.

Acted as the lead lawyer for Fu'an Pharmaceutical's (300194) acquisition of Zhichu Pharmaceutical's 100% equity through share issuance and cash payment, along with raising supporting funds (a connected transaction), assisting in obtaining regulatory approval and completion of the transaction.

Acted as the lead lawyer for Quartz (603688) public issuance of convertible corporate bonds, assisting in obtaining regulatory approval and successful issuance.

Acted as the lead lawyer for Beingmate's (002570) issuance of short-term financing bills, assisting in successful registration and issuance.

Acted as the lead lawyer for the NEEQ listings of Zanhe (870514), Daishan Electric Power (835745), Tianqing (837725), Hengjing Induction (834094), Xinong (831868), Shanghai Qinghe (832572), Yili Capsule (832174), and Hengdao Pharmaceutical (873870), assisting these companies in successfully listing on the National Equities Exchange and Quotations.

Acted as the lead lawyer for the private placement of stocks for Yili Capsule (832174), Fuzhan Technology (830903), Roman (430662), Haiyang (830921), and the major asset reorganization of Hengdao Pharmaceutical (873870), assisting in the successful execution of these projects.

Acted as the lead lawyer for equity incentive plans and employee stock ownership plans of listed companies such as Quartz (603688) and Suzhou Keda (603660), assisting in their successful implementation.

Acted as the lead lawyer for public issuance of corporate bonds, ultra-short-term financing bills, and medium-term notes for subsidiaries of State Grid and China State Construction, assisting in successful registration and issuance.

Corporate Business

Represented a central state-owned enterprise listed company (SSE Main Board) in providing full legal services for due diligence/acquisition projects of several wind, photovoltaic, and hydropower projects.

Represented a central state-owned enterprise listed company (SSE Main Board) in providing full legal services for the establishment of new energy joint ventures with other large state-owned enterprises in various districts of Shanghai.

Represented a listed company (SSE Main Board) in providing full legal services for due diligence/acquisition projects of several quartz product enterprises.

Represented a listed company (SZSE ChiNext) in providing full legal services for the acquisition of a pharmaceutical distribution company.

Represented a listed company (SZSE ChiNext) in providing full legal services for due diligence/acquisition projects of a pharmaceutical distribution company, a gene therapy company, and a traditional Chinese medicine company.

Represented a listed company (Hong Kong) in providing full legal services for the acquisition of a microfinance company.

Represented a listed company (SZSE Main Board) in providing full legal services for an asset divestiture project.

Served as the regular legal counsel for multiple listed companies (STAR Market, ChiNext, SSE & SZSE Main Boards), providing daily legal services including lawyer notarization, investment and M&A, information disclosure, compliance operations, corporate governance, and legal consultation.

Served as the special legal counsel for multiple pre-IPO enterprises, providing services such as compliance coaching, equity structure design, compliance operations, and corporate governance.

Served as the regular legal counsel for multiple pre-IPO enterprises, providing legal consultation, contract drafting and review, commercial negotiation, compliance operation, legal training, and issuance of legal documents.

Health and Life Sciences

Acted as the lead lawyer for the STAR Market listing of a pharmaceutical enterprise (engaged in R&D, production, and sales of anti-tumor and injectable drugs), assisting in its successful listing on the STAR Market.

Acted as the lead lawyer for the NEEQ listing and major asset reorganization of a CRO enterprise (providing pharmaceutical R&D services and drug production/sales), assisting in its successful listing and asset reorganization.

Acted as the lead lawyer for a listed pharmaceutical company (engaged in R&D, production, and sales of chemical drugs) in its acquisition of assets (major asset reorganization) through share issuance and cash payment, assisting in the project's smooth approval and completion.

Represented a listed pharmaceutical company (engaged in R&D, production, and sales of chemical drugs) in providing full legal services for the M&A project of a pharmaceutical distribution company.

Represented a listed pharmaceutical company (in the traditional Chinese medicine industry) in providing full legal services for the M&A project of a pharmaceutical distribution company.

Represented a well-known investment institution in reaching cooperation with an innovative drug company (Hong Kong listed) to jointly invest in a new drug R&D company (Newco) focused on using universal CAR-T cell therapy to treat hematological tumors, providing full legal services.

Represented a listed pharmaceutical company (in the traditional Chinese medicine industry) in reaching an investment cooperation with an innovative drug company (a globally leading company in innovative drug development for single-gene genetic diseases), providing full legal services.

Represented a listed pharmaceutical company in leading an investment in a pre-Hong Kong listing innovative drug company (which later successfully listed) and provided full legal services.

Acted as the representative lawyer in a technology development contract dispute case between a CRO enterprise and a pharmaceutical company, achieving a final victory after first instance in the Intermediate Court and second instance in the Provincial High Court.

Served as the regular legal counsel for multiple pharmaceutical enterprises, including a comprehensive pharmaceutical company, an integrated API + preparation company, a gene therapy innovative drug company, a cell therapy innovative drug company, a CRO company, an MAH model pharmaceutical company, a B-certificate pharmaceutical company, an API + CDMO pharmaceutical company, and a pharmaceutical agency (CSO), providing legal services covering R&D and registration, production and operation, marketing and distribution, corporate governance, daily operational support, compliance system building, licensing and transactions, investment and financing and M&A, dispute resolution, and regulatory response.
